---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221658"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2026-05-13T20:15:17+00:00"
generated_at: "2026-05-13T20:16:22.801620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial

## Summary
- Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.
- Net loss $39.0M ($0.33/share) vs $6.5M ($0.08/share) in Q1 2025; includes $19M non-cash loss from warrant liabilities.
- R&D expense $17.2M (incl. $1.1M stock comp) vs $13.5M in prior year; G&A $4.0M vs $4.4M.
- 10/10 evaluable patients achieved 100% insulin independence with tegoprubart in islet transplantation; no rejection or tacrolimus-like toxicities.
- FDA granted Orphan Drug designation for tegoprubart in liver transplantation; Phase 3 kidney trial design guidance expected from FDA.

## SEC filing metadata
- accession: 0001193125-26-221658
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2026-05-13T20:15:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/0001193125-26-221658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221658
- JSON: https://secwatch.observer/filing/0001193125-26-221658.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.